Charles River: 2016 to be 'robust year'
After reporting a successful FY16, Charles River expects a successful new year driven by customer demand and enhanced strategic partnerships.
After reporting a successful FY16, Charles River expects a successful new year driven by customer demand and enhanced strategic partnerships.
The US Government is set to extend an anthrax vaccine supply contract, and Emergent Biosolutions believes its new commercial-scale facility coming online was a driving factor.
Grupo Ferrer Internacional will acquire Alexza Pharmaceuticals for around $2m, adding the Staccato aerosol system to its drug delivery offerings.
Recent capacity growth means the UK will be a cell and gene therapy hub for years to come according to the authors of a new manufacturing survey.
A remediation plan by Medreich Limited is sufficient to bring its Andhra Pradesh antibiotics plant in to compliance with GMP according to French regulator ANSM.